Xbp1, cd138, and cs1 peptides
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNikhil C. Munshi, Kenneth C. Anderson, Jooeun Bae
Life of this patent
Estimating the term…
Abstract
The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in WIC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
Claims21
-128. (canceled)
A method for inducing an immune response in a subject, the method comprising administering to the subject a composition comprising:
- (a) a first XBP-1 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:6, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 6, which, if present, are amino acids that flank SEQ ID NO:
- 2 in non-spliced XBP1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO:
- 6, which, if present, are amino acids that flank SEQ ID NO:
- 2 in non-spliced XBP1;
- (b) a second XBP-1 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:10, and (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 10, which, if present, are amino acids that flank SEQ ID NO:
- 9 in spliced XBP1;
- and
- (c) a CD138 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:12, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 12, which, if present, are amino acids that flank SEQ ID NO:
- 12 in CD138, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO:
- 12, which, if present, are amino acids that flank SEQ ID NO:
- 12 in CD138.
A composition comprising:
- (a) a first XBP-1 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:6, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 6, which, if present, are amino acids that flank SEQ ID NO:
- 2 in non-spliced XBP1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO:
- 6, which, if present, are amino acids that flank SEQ ID NO:
- 2 in non-spliced XBP1;
- or
- (b) a second XBP-1 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:10, and (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 10, which, if present, are amino acids that flank SEQ ID NO:
- 9 in spliced XBP1.
A composition comprising a CS-1 peptide comprising:
- (i) the amino acid sequence of SEQ ID NO:
- 16, (ii) 0 to up to 10 amino acids immediately N-terminal of SEQ ID NO:
- 16, which, if present, are amino acids that flank SEQ ID NO:
- 16 in CS-1, and (iii) 0 to up to 10 amino acids immediately C-terminal of SEQ ID NO:
- 16, which, if present, are amino acids that flank SEQ ID NO:
- 16 in CS-1.
Dependencies are inferred from the claim text.